ERBB2 and colorectal carcinoma: However, the authors of the study reported a lower objective response rate (ORR) to anti-EGFR therapies in HER2-amplified CRC patients and relied on a strong biological rationale, as HER2 overexpression represents an alternative pathway to obviate EGFR signaling in tumorigenesis and/or in tumor progression [101,120].